Pfizer Inc. (NYSE:PFE) Shares Purchased by Bogart Wealth LLC

Bogart Wealth LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 52.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 366,253 shares of the biopharmaceutical company’s stock after buying an additional 126,501 shares during the quarter. Bogart Wealth LLC’s holdings in Pfizer were worth $9,717,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in PFE. Asset Management One Co. Ltd. lifted its position in Pfizer by 5.0% in the fourth quarter. Asset Management One Co. Ltd. now owns 2,392,759 shares of the biopharmaceutical company’s stock valued at $63,695,000 after buying an additional 114,090 shares during the last quarter. Life Planning Partners Inc acquired a new position in Pfizer during the 4th quarter worth $893,000. Beckerman Institutional LLC grew its position in shares of Pfizer by 27.2% during the fourth quarter. Beckerman Institutional LLC now owns 16,538 shares of the biopharmaceutical company’s stock worth $439,000 after buying an additional 3,540 shares in the last quarter. Raab & Moskowitz Asset Management LLC raised its holdings in shares of Pfizer by 10.2% in the 4th quarter. Raab & Moskowitz Asset Management LLC now owns 285,567 shares of the biopharmaceutical company’s stock valued at $7,576,000 after purchasing an additional 26,433 shares in the last quarter. Finally, Van ECK Associates Corp raised its stake in Pfizer by 28.5% in the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock valued at $564,739,000 after buying an additional 4,726,549 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 0.7 %

Shares of NYSE PFE opened at $25.64 on Friday. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The firm has a market cap of $145.28 billion, a P/E ratio of 18.18, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The firm’s 50 day moving average price is $26.28 and its 200 day moving average price is $27.63. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period last year, the company earned $0.10 earnings per share. The company’s quarterly revenue was up 24.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.71%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is presently 121.99%.

Analyst Ratings Changes

PFE has been the subject of several recent analyst reports. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup dropped their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Bank of America reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Finally, Sanford C. Bernstein began coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.